Atossa Therapeutics requests Type C meeting with U.S. FDA

 Atossa Therapeutics (ATOS) announced it has requested a Type C meeting with the U.S. Food and Drug Administration, FDA, to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. Atossa is a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and risk-reduction, commonly termed prevention of breast cancer.

https://www.tipranks.com/news/the-fly/atossa-therapeutics-has-requested-type-c-meeting-with-u-s-fda-thefly